

24/7 Market News- Biotech Headlines

DENVER, CO, USA, July 16, 2020 /EINPresswire.com/ -- Today's [biotech](#) headlines include developments from Emmaus Life Sciences, Inc. (OTCQB:EMMA), AC Immune SA ([NASDAQ:ACIU](#)), and Nabriva Therapeutics plc (NASDAQ:NBV).



Our firm is extremely proud to represent Emmaus...this is a serious unmet medical need with significant market potential worldwide."

*Joanne Ball-Gautschi, CEO
and President, Partner
International*

Emmaus Life Sciences, Inc. (OTCQB:EMMA), a leader in sickle cell disease treatment, announced this morning that it engaged Partner International "to lead the out-licensing activity for Emmaus' prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis. This is the same active pharmaceutical ingredient found in Endari(R), which is approved by the FDA and the Israeli Ministry of Health to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older."

"Diverticulosis is an often asymptomatic gastrointestinal (GI) condition affecting a large segment of the adult populations in the U.S. and elsewhere. It can sometimes progress to diverticulitis, a debilitating GI disease that often requires hospitalization and on occasion surgical intervention. Based upon limited clinical results suggesting that Endari(R) may be effective in slowing and reversing the progression of diverticulosis, in April 2019 Emmaus commenced a Pilot/Phase 1 study of its PGLG oral powder to evaluate the change in the number and size of colonic diverticula and assess safety in 10 to 15 patients at multiple study sites. A preliminary interim evaluation of the first patients in the study indicates consistently positive results. Although the trial is ongoing, based upon the data obtained so far, Emmaus would intend to pursue a Phase III trial under the FDA's abbreviated 505(b)(2) regulatory pathway."

"With no current treatment options available, this is a serious unmet medical need with significant market potential worldwide," stated Joanne Ball-Gautschi, CEO and President of Partner International

Swiss-based AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, announced overnight "the initiation of the second highest dosing group in the Company's Phase 1b/2a clinical trial evaluating ACI-35.030 for the treatment of Alzheimer's disease (AD). The decision to advance to the higher dosing group follows encouraging interim safety, tolerability and immunogenicity results from the initial dosing group."

"Immunization with anti-Tau vaccines has become an important strategy for the treatment of AD and other neurodegenerative diseases characterized by Tau pathology. ACI-35.030, which is being developed in collaboration with Janssen Pharmaceuticals, Inc., is the first AD vaccine candidate designed to generate a specific antibody response against pathologic phospho-Tau (pTau) proteins in the brain. Anti-pTau antibodies generated by ACI-35.030 have the potential to reduce the spread and seeding of Tau pathology throughout the brain."

"The fact that ACI-35.030 shows encouraging safety and immunogenicity at the lowest dose in this elderly patient population is highly meaningful and we look forward to quickly enrolling this next dosing group," Prof. Andrea Pfeifer, CEO of AC Immune SA, said.

Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced, after yesterday's market close, that it has entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA "to market, sell and distribute SIVEXTRO(R) (tedizolid phosphate) in the United States and certain of its territories. SIVEXTRO is an oxazolidinone-class antibacterial indicated in adults and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible Gram-positive microorganisms."

Connect with 24/7 Market News on social media:

<https://twitter.com/247MarketNewsHQ>

<https://www.facebook.com/247MarketNewsHQ/>

About 24/7 Market News

As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community.

DISCLAIMER:

24/7 Market News (24/7MN) is a third party publisher and news dissemination service provider that produces regular sponsored and non-sponsored reports, articles, [stock market](#) blogs, and newsletters covering equities listed on the NYSE, NASDAQ and micro-cap exchanges. 24/7MN holds no investment licenses and is NOT a financial advisory firm, investment adviser, analyst, or broker-dealer and does not undertake any activities that would require such registration. 24/7MN's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.

Materials in this release are informational and should never be considered research. You must do your own due diligence by reading all available public information. This release is a corporate public statement, and believed to be reliable. The principle and editor of 24/7 currently owns no

shares of the aforementioned companies, but has the right to buy and sell at any time of his choosing which could be viewed as a conflict of interest. 24/7 makes no representations and warranties to the completeness of materials provided and are subject to change without notice. 24/7 is not responsible for any gains or losses which result from our opinions or coverage expressed in our emails or our site and readers are cautioned that investing has risks and you may lose all or a portion of your money.

For further information on 24/7 Market News, please go to www.247marketnews.com

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

CONTACT:

24/7 Market News

Editor@247marketnews.com

24/7 Market News

24/7 Market News

+1 720-580-2740

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/521843688>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.